Logo image of BCAL

CALIFORNIA BANCORP (BCAL) Stock Fundamental Analysis

NASDAQ:BCAL - Nasdaq - US84252A1060 - Common Stock - Currency: USD

16.2  -0.2 (-1.22%)

After market: 16.2 0 (0%)

Fundamental Rating

4

BCAL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 397 industry peers in the Banks industry. BCAL has a bad profitability rating. Also its financial health evaluation is rather negative. BCAL is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

BCAL had positive earnings in the past year.
BCAL had a positive operating cash flow in the past year.
BCAL Yearly Net Income VS EBIT VS OCF VS FCFBCAL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 20M 40M 60M 80M

1.2 Ratios

With a Return On Assets value of 0.44%, BCAL is not doing good in the industry: 79.09% of the companies in the same industry are doing better.
With a Return On Equity value of 3.27%, BCAL is not doing good in the industry: 83.12% of the companies in the same industry are doing better.
BCAL has a Return On Invested Capital of 1.83%. This is amongst the best in the industry. BCAL outperforms 99.24% of its industry peers.
BCAL had an Average Return On Invested Capital over the past 3 years of 1.52%. This is in line with the industry average of 2.64%.
The 3 year average ROIC (1.52%) for BCAL is below the current ROIC(1.83%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.44%
ROE 3.27%
ROIC 1.83%
ROA(3y)0.65%
ROA(5y)N/A
ROE(3y)5.41%
ROE(5y)N/A
ROIC(3y)1.52%
ROIC(5y)N/A
BCAL Yearly ROA, ROE, ROICBCAL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2 4 6 8

1.3 Margins

BCAL has a worse Profit Margin (8.47%) than 84.63% of its industry peers.
In the last couple of years the Profit Margin of BCAL has declined.
Looking at the Operating Margin, with a value of 51.92%, BCAL belongs to the top of the industry, outperforming 99.75% of the companies in the same industry.
BCAL's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 51.92%
PM (TTM) 8.47%
GM N/A
OM growth 3Y19.95%
OM growth 5YN/A
PM growth 3Y-42.04%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAL Yearly Profit, Operating, Gross MarginsBCAL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40 50

3

2. Health

2.1 Basic Checks

BCAL has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BCAL has more shares outstanding than it did 1 year ago.
BCAL has a better debt/assets ratio than last year.
BCAL Yearly Shares OutstandingBCAL Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
BCAL Yearly Total Debt VS Total AssetsBCAL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of -0.72, we must say that BCAL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.72, BCAL belongs to the top of the industry, outperforming 98.99% of the companies in the same industry.
The Debt to FCF ratio of BCAL is 70.14, which is on the high side as it means it would take BCAL, 70.14 years of fcf income to pay off all of its debts.
BCAL has a worse Debt to FCF ratio (70.14) than 86.40% of its industry peers.
BCAL has a Debt/Equity ratio of 6.42. This is a high value indicating a heavy dependency on external financing.
BCAL has a Debt to Equity ratio of 6.42. This is amonst the worse of the industry: BCAL underperforms 97.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 6.42
Debt/FCF 70.14
Altman-Z -0.72
ROIC/WACC0.51
WACC3.63%
BCAL Yearly LT Debt VS Equity VS FCFBCAL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

BCAL has a Current Ratio of 0.03. This is a bad value and indicates that BCAL is not financially healthy enough and could expect problems in meeting its short term obligations.
BCAL has a better Current ratio (0.03) than 99.24% of its industry peers.
BCAL has a Quick Ratio of 0.03. This is a bad value and indicates that BCAL is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.03, BCAL belongs to the top of the industry, outperforming 99.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.03
Quick Ratio 0.03
BCAL Yearly Current Assets VS Current LiabilitesBCAL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 1B 2B 3B

8

3. Growth

3.1 Past

BCAL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.18%.
Measured over the past years, BCAL shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -28.36% on average per year.
The Revenue has grown by 63.83% in the past year. This is a very strong growth!
The Revenue has been growing by 37.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-18.18%
EPS 3Y-28.36%
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)63.83%
Revenue growth 3Y37.61%
Revenue growth 5YN/A
Sales Q2Q%104.6%

3.2 Future

Based on estimates for the next years, BCAL will show a very strong growth in Earnings Per Share. The EPS will grow by 54.53% on average per year.
The Revenue is expected to grow by 20.93% on average over the next years. This is a very strong growth
EPS Next Y139.72%
EPS Next 2Y54.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year39.39%
Revenue Next 2Y20.93%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BCAL Yearly Revenue VS EstimatesBCAL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 50M 100M 150M
BCAL Yearly EPS VS EstimatesBCAL Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0.5 1 1.5

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 16.36 indicates a correct valuation of BCAL.
Compared to the rest of the industry, the Price/Earnings ratio of BCAL indicates a slightly more expensive valuation: BCAL is more expensive than 71.54% of the companies listed in the same industry.
BCAL is valuated rather cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.29, which indicates a very decent valuation of BCAL.
BCAL's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BCAL is cheaper than 67.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.76. BCAL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.36
Fwd PE 9.29
BCAL Price Earnings VS Forward Price EarningsBCAL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BCAL is valued cheaply inside the industry as 99.50% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BCAL is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 10.79
EV/EBITDA 4.69
BCAL Per share dataBCAL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BCAL's earnings are expected to grow with 54.53% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y54.53%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BCAL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CALIFORNIA BANCORP

NASDAQ:BCAL (7/11/2025, 8:00:02 PM)

After market: 16.2 0 (0%)

16.2

-0.2 (-1.22%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)04-24 2025-04-24/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners56.98%
Inst Owner Change0%
Ins Owners24.22%
Ins Owner Change-0.08%
Market Cap525.04M
Analysts80
Price Target18.02 (11.23%)
Short Float %1.73%
Short Ratio3.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.54%
Min EPS beat(2)13.64%
Max EPS beat(2)27.45%
EPS beat(4)3
Avg EPS beat(4)8.04%
Min EPS beat(4)-96.35%
Max EPS beat(4)87.43%
EPS beat(8)3
Avg EPS beat(8)-1.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.46%
Min Revenue beat(2)-8.89%
Max Revenue beat(2)-2.03%
Revenue beat(4)0
Avg Revenue beat(4)-3.69%
Min Revenue beat(4)-8.89%
Max Revenue beat(4)-1.17%
Revenue beat(8)0
Avg Revenue beat(8)-4.98%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.67%
EPS NQ rev (1m)0.99%
EPS NQ rev (3m)-2.4%
EPS NY rev (1m)0%
EPS NY rev (3m)2.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.48%
Valuation
Industry RankSector Rank
PE 16.36
Fwd PE 9.29
P/S 2.56
P/FCF 10.79
P/OCF 10.67
P/B 0.99
P/tB 1.32
EV/EBITDA 4.69
EPS(TTM)0.99
EY6.11%
EPS(NY)1.74
Fwd EY10.76%
FCF(TTM)1.5
FCFY9.27%
OCF(TTM)1.52
OCFY9.37%
SpS6.32
BVpS16.4
TBVpS12.29
PEG (NY)0.12
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.44%
ROE 3.27%
ROCE 17.68%
ROIC 1.83%
ROICexc 1.87%
ROICexgc 1.98%
OM 51.92%
PM (TTM) 8.47%
GM N/A
FCFM 23.75%
ROA(3y)0.65%
ROA(5y)N/A
ROE(3y)5.41%
ROE(5y)N/A
ROIC(3y)1.52%
ROIC(5y)N/A
ROICexc(3y)1.54%
ROICexc(5y)N/A
ROICexgc(3y)1.61%
ROICexgc(5y)N/A
ROCE(3y)15.77%
ROCE(5y)N/A
ROICexcg growth 3Y37.36%
ROICexcg growth 5YN/A
ROICexc growth 3Y36.52%
ROICexc growth 5YN/A
OM growth 3Y19.95%
OM growth 5YN/A
PM growth 3Y-42.04%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 6.42
Debt/FCF 70.14
Debt/EBITDA 30.73
Cap/Depr 12.1%
Cap/Sales 0.28%
Interest Coverage 1.79
Cash Conversion 44.32%
Profit Quality 280.41%
Current Ratio 0.03
Quick Ratio 0.03
Altman-Z -0.72
F-Score4
WACC3.63%
ROIC/WACC0.51
Cap/Depr(3y)28.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.57%
Cap/Sales(5y)N/A
Profit Quality(3y)372.76%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.18%
EPS 3Y-28.36%
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y139.72%
EPS Next 2Y54.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)63.83%
Revenue growth 3Y37.61%
Revenue growth 5YN/A
Sales Q2Q%104.6%
Revenue Next Year39.39%
Revenue Next 2Y20.93%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y53.59%
EBIT growth 3Y65.06%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.47%
FCF growth 3Y40.59%
FCF growth 5YN/A
OCF growth 1Y40.59%
OCF growth 3Y36.79%
OCF growth 5YN/A